Table 5.
Possible applications of new antibiotics against Gram-negative bacteria based on resistant mechanisms.
| ESBL and AmpC | KPC | OXA-48 | MBL | Carbapenem Nonsusceptible A. baumanii | Carbapenem Nonsusceptible P. aeruginosa | |
|---|---|---|---|---|---|---|
| Plazomicin | ++ | ++ | ++ | +/− a | − | − |
| Eravacycline | ++ | ++ | ++ | + b | ++ | − |
| Temocillin | ++ (urine breakpoint only) | ++ (urine breakpoint only) | − | − | − | − |
| Cefiderocol | ++ | ++ | ++ | ++ | ++ | ++ |
| Ceftazidime/avibactam | ++ | ++ | ++ | − | − | +/− |
| Ceftolozane/tazobactam | ++ | − | − | − | − | +/− c |
| Meropenem/vaborbactam | ++ | ++ | − | − | ? | ? |
| Imipenem/relebactam | ++ | ++ | − | − | − | +/− d |
++: Activity (>90% of the isolates); +: activity in 70 to 90% of the isolates; +/−: activity in around the half of the; −: no activity; ?: no surveillance data available. a 42.1% susceptible isolates [12]; b 70% susceptible isolates [32]; c good activity against isolates with elevated efflux, derepressed AmpC or loss of OprD, but not when the underlying mechanism is MBL production [82]; d not for isolates with class B or D carbapenemase activity [83].